7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide | 454685-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide
• CAS: 454685-89-3
• 化学式: C₇H₆N₄O
• mdl: MFCD18810491
• 分子量: 162.15
• InChiKey: DYMCRSCIKQMSRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20200054617A1

  公开（公告）日：2020-02-20

  Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

  式(I)的杂环芳基羧酰胺，其中Y、R和X如本文所定义，并其药学上可接受的盐。式(I)的化合物可用于治疗受血浆激肽酶抑制影响的疾病的方法。
• NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2947086A1

  公开（公告）日：2015-11-25

  Provided is a novel compound having BTK inhibitory action and a cell proliferation suppressing effect. Also provided is a medicine useful for the prevention and/or treatment of a disease associated with BTK, particularly cancer, based on BTK inhibitory action. A compound represented by formula (I) [wherein R1 to R3, W, A, Y and Z respectively have the meanings as defined in the specification], or a salt thereof is disclosed.

  本发明提供了一种具有 BTK 抑制作用和细胞增殖抑制效果的新型化合物。还提供了一种基于 BTK 抑制作用的药物，可用于预防和/或治疗与 BTK 有关的疾病，特别是癌症。本发明公开了一种由式（I）[其中 R1 至 R3、W、A、Y 和 Z 分别具有说明书中定义的含义]代表的化合物或其盐。
• PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR IMMUNE DISEASES
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3120852A1

  公开（公告）日：2017-01-25

  Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R1 to R3, W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.

  本发明提供了一种免疫疾病的预防和/或治疗剂，其活性成分包含一种具有 BTK 抑制活性的化合物或其盐。 一种免疫疾病的预防和/或治疗剂，包含由式（I）代表的化合物（其中 R1 至 R3、W、X、Y、Z 和 n 代表说明书中定义的那些）或其盐作为活性成分。
• Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10695334B2

  公开（公告）日：2020-06-30

  Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.

  式 (I) 的杂芳香族羧酰胺、 其中 Y、R 和 X 如本文所定义，及其药学上可接受的盐类。式（I）化合物可用于治疗可受血浆卡利克林抑制影响的疾病的方法中。
• CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER
  申请人：SNU R&DB Foundation

  公开号：EP2636677B1

  公开（公告）日：2016-01-13